[go: up one dir, main page]

LT3515938T - Monokloniniai antikūnai prieš programuojamą mirtį 1 (pd-1) - Google Patents

Monokloniniai antikūnai prieš programuojamą mirtį 1 (pd-1)

Info

Publication number
LT3515938T
LT3515938T LTEPPCT/CN2016/099576T LTCN2016099576T LT3515938T LT 3515938 T LT3515938 T LT 3515938T LT CN2016099576 T LTCN2016099576 T LT CN2016099576T LT 3515938 T LT3515938 T LT 3515938T
Authority
LT
Lithuania
Prior art keywords
monoclonal antibodies
programmed death
death
programmed
monoclonal
Prior art date
Application number
LTEPPCT/CN2016/099576T
Other languages
English (en)
Inventor
Yong Zheng
Jing Li
Gennady Gololobov
Xinhua Zhang
Baotian YANG
Zhewei TANG
Dong Li
Jianqing Xu
Zhuozhi Wang
Original Assignee
Cstone Pharmaceuticals
Cstone Pharmaceuticals (Suzhou) Co., Ltd.
Cstone Pharmaceuticals (Shanghai) Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cstone Pharmaceuticals, Cstone Pharmaceuticals (Suzhou) Co., Ltd., Cstone Pharmaceuticals (Shanghai) Co., Ltd. filed Critical Cstone Pharmaceuticals
Publication of LT3515938T publication Critical patent/LT3515938T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74Inducing cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
LTEPPCT/CN2016/099576T 2016-09-21 2016-09-21 Monokloniniai antikūnai prieš programuojamą mirtį 1 (pd-1) LT3515938T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2016/099576 WO2018053709A1 (en) 2016-09-21 2016-09-21 The novel monoclonal antibodies to programmed death 1 (pd-1)

Publications (1)

Publication Number Publication Date
LT3515938T true LT3515938T (lt) 2025-05-12

Family

ID=61690082

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/CN2016/099576T LT3515938T (lt) 2016-09-21 2016-09-21 Monokloniniai antikūnai prieš programuojamą mirtį 1 (pd-1)

Country Status (23)

Country Link
US (3) US11414487B2 (lt)
EP (2) EP4450616A3 (lt)
JP (2) JP7101169B2 (lt)
KR (2) KR102527160B1 (lt)
AU (1) AU2016423559C1 (lt)
BR (1) BR112019005316A2 (lt)
CA (1) CA3037407C (lt)
DK (1) DK3515938T3 (lt)
ES (1) ES3017957T3 (lt)
FI (1) FI3515938T3 (lt)
HR (1) HRP20250400T1 (lt)
HU (1) HUE071253T2 (lt)
IL (1) IL265525A (lt)
LT (1) LT3515938T (lt)
MX (1) MX2019003058A (lt)
PL (1) PL3515938T3 (lt)
PT (1) PT3515938T (lt)
RS (1) RS66679B1 (lt)
RU (1) RU2757316C2 (lt)
SA (1) SA519401370B1 (lt)
SI (1) SI3515938T1 (lt)
SM (1) SMT202500148T1 (lt)
WO (1) WO2018053709A1 (lt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3334763T3 (da) 2015-08-11 2024-10-07 Wuxi Biologics Ireland Ltd Nye anti-PD-1-antistoffer
LT3370768T (lt) 2015-11-03 2022-05-25 Janssen Biotech, Inc. Antikūnai, specifiškai surišantys pd-1, ir jų panaudojimas
DK3515938T3 (da) * 2016-09-21 2025-04-07 Cstone Pharmaceuticals Monoklonale antistoffer mod programmeret død 1 (pd-1)
HUE057559T2 (hu) 2016-11-02 2022-06-28 Jounce Therapeutics Inc PD-1 elleni antitestek és alkalmazásaik
SI3661954T1 (sl) 2017-08-03 2022-05-31 Amgen Inc. Muteini interlevkina-21 in postopki zdravljenja
UY38049A (es) 2018-01-12 2019-07-31 Amgen Inc Anti-pd-1 anticuerpos y métodos de tratamiento
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
KR102558418B1 (ko) 2018-04-15 2023-07-24 임비라 컴퍼니 리미티드 Pd-1에 결합하는 항체 및 그 용도
WO2019201169A1 (en) * 2018-04-15 2019-10-24 Salubris (Chengdu) Biotech Co., Ltd Antibodies binding pd-1 and uses thereof
CN109160949B (zh) * 2018-07-23 2021-05-14 中国医学科学院血液病医院(血液学研究所) 一种鼠抗人pd-1单克隆抗体及应用
SG11202111441QA (en) * 2019-04-26 2021-11-29 Wuxi Biologics Ireland Ltd Bispecific antibodies against pd-1 and lag-3
US20220241412A1 (en) 2019-05-24 2022-08-04 Pfizer Inc. Combination therapies using cdk inhibitors
KR102866812B1 (ko) * 2019-09-25 2025-10-02 우시 바이올로직스 아일랜드 리미티드 신규한 항-pd-l1 항체
WO2021093764A1 (en) * 2019-11-11 2021-05-20 Cstone Pharmaceuticals (Suzhou) Co., Ltd. Pharmaceutical combination and use thereof
WO2021110122A1 (zh) * 2019-12-05 2021-06-10 基石药业(苏州)有限公司 Cdk4/6抑制剂的组合疗法
PL4157876T3 (pl) 2020-05-26 2025-02-03 Boehringer Ingelheim International Gmbh Przeciwciała anty-pd-1
CA3191749A1 (en) * 2020-08-31 2022-03-03 Biosion Inc. Pd-1 binding antibodies and uses thereof
WO2022068919A1 (zh) * 2020-09-30 2022-04-07 正大天晴康方(上海)生物医药科技有限公司 结合pd-1抗体的肽及其应用
US20220168293A1 (en) 2020-12-02 2022-06-02 Pfizer Inc. Time to resolution of axitinib-related adverse events
AU2022217058A1 (en) 2021-02-04 2023-09-21 Genuv Inc. Anti-pd-1 antibody and use thereof
WO2023057882A1 (en) 2021-10-05 2023-04-13 Pfizer Inc. Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist
CN116036266A (zh) * 2022-12-28 2023-05-02 广州誉衡生物科技有限公司 抗-pd-1抗体及其在制备治疗结肠癌患者的药物中的用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006021955A2 (en) 2004-08-23 2006-03-02 Mor Research Applications Ltd. Use of bat monoclonal antibody for immunotherapy
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
US7662965B2 (en) * 2006-01-26 2010-02-16 Cornerstone Therapeutics, Inc. Anabaseine derivatives, pharmaceutical compositions and method of use thereof
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
JP6285414B2 (ja) * 2012-03-30 2018-02-28 モルフォテック, インコーポレイテッド Tem−1診断用抗体
JOP20200094A1 (ar) * 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CN105330740B (zh) * 2014-07-30 2018-08-17 珠海市丽珠单抗生物技术有限公司 抗pd-1抗体及其应用
EP3218409A2 (en) 2014-11-11 2017-09-20 Sutro Biopharma, Inc. Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗pd-1抗體類和使用彼等之方法
WO2016127179A2 (en) * 2015-02-06 2016-08-11 Kadmon Corporation, Llc Immunomodulatory agents
DK3334763T3 (da) * 2015-08-11 2024-10-07 Wuxi Biologics Ireland Ltd Nye anti-PD-1-antistoffer
CA3000564A1 (en) 2015-10-02 2017-04-06 Symphogen A/S Anti-pd-1 antibodies and compositions
DK3515938T3 (da) * 2016-09-21 2025-04-07 Cstone Pharmaceuticals Monoklonale antistoffer mod programmeret død 1 (pd-1)
WO2019062755A1 (en) * 2017-09-29 2019-04-04 Wuxi Biologics (Shanghai) Co., Ltd. BISPECIFIC ANTIBODIES DIRECTED AGAINST EGFR AND PD-1
WO2021093764A1 (en) * 2019-11-11 2021-05-20 Cstone Pharmaceuticals (Suzhou) Co., Ltd. Pharmaceutical combination and use thereof

Also Published As

Publication number Publication date
RU2019111277A (ru) 2020-10-23
IL265525A (en) 2019-05-30
RS66679B1 (sr) 2025-05-30
EP4450616A3 (en) 2025-01-01
DK3515938T3 (da) 2025-04-07
PT3515938T (pt) 2025-04-10
AU2016423559B2 (en) 2020-07-30
CA3037407A1 (en) 2018-03-29
JP2019536432A (ja) 2019-12-19
ES3017957T3 (en) 2025-05-14
KR102273634B1 (ko) 2021-07-07
JP7101169B2 (ja) 2022-07-14
EP3515938A1 (en) 2019-07-31
PL3515938T3 (pl) 2025-06-09
MX2019003058A (es) 2019-11-28
KR20190072524A (ko) 2019-06-25
WO2018053709A1 (en) 2018-03-29
EP3515938A4 (en) 2020-06-10
SMT202500148T1 (it) 2025-05-12
CA3037407C (en) 2022-10-18
BR112019005316A2 (pt) 2019-09-03
US11414487B2 (en) 2022-08-16
AU2016423559A1 (en) 2019-04-04
KR102527160B1 (ko) 2023-04-28
RU2019111277A3 (lt) 2020-10-23
EP3515938B8 (en) 2025-04-30
EP4450616A2 (en) 2024-10-23
US20240101676A1 (en) 2024-03-28
KR20210104749A (ko) 2021-08-25
US20230014722A1 (en) 2023-01-19
HUE071253T2 (hu) 2025-08-28
AU2016423559C1 (en) 2020-11-19
HRP20250400T1 (hr) 2025-05-09
SI3515938T1 (sl) 2025-05-30
EP3515938B1 (en) 2025-01-08
RU2757316C2 (ru) 2021-10-13
US20200002420A1 (en) 2020-01-02
JP2021120378A (ja) 2021-08-19
FI3515938T3 (fi) 2025-03-27
SA519401370B1 (ar) 2024-02-27

Similar Documents

Publication Publication Date Title
IL265525A (en) New monoclonal antibodies against pd-1
HUS2500002I1 (hu) Újszerû anti-PD-L1 antitestek
ZA201900353B (en) Anti-pd-l1 antibodies
IL261188A (en) Antibodies against tigit
IL262295A (en) Antibodies against pd-l1
IL256922A (en) Pd-l1 (" programmed death-ligand 1" ) antibodies
IL266229A (en) Antibodies directed against pd-1
IL255727A (en) Novel anti-pd-l1 antibodies
SG10201603721TA (en) Anti-CTLA-4 Antibodies
ZA201807167B (en) Humanized anti-il-1r3 antibodies
IL272911A (en) Antibodies to programmed cell death protein 1 (PD-1)
ZA201907065B (en) Monoclonal antibody to pd-l1
LT3484446T (lt) Antikūno kompozicijos
EP3559044A4 (en) IMMUNOTHERAPY USING ANTIBODIES THAT BINDING PROGRAMMED CELL DEATH 1 (PD-1)
SMT202100185T1 (it) Anticorpi umanizzati anti-cd28 formulati per somministrazione agli essere umani
GB201609742D0 (en) Improvements relating to antibodies
GB201511196D0 (en) Monoclonal antibodies
GB201700208D0 (en) Single domain antibodies to programmed cell death (PD-1)
GB201700210D0 (en) Single domain antibodies to programmed cell death (PD-1)
PT3390450T (pt) Anticorpos humanizados anti-cd28 formulados para administração a humanos
HK40034252A (en) Antibodies to programmed cell death protein 1
GB201621446D0 (en) IL-11 antibodies
GB201709535D0 (en) IL-11 Antibodies